Mucormycosis: An unanticipated progeny of COVID-19
DOI:
https://doi.org/10.31729/jnma.6686Keywords:
COVID-19, mucormycosis, NepalAbstract
The rapid surge of COVID-19 cases in the second wave of the pandemic has crippled the healthcare delivery system in Nepal and neighboring countries. Unlike in the first wave of the pandemic, several cases of mucormycosis have been reported in patients with COVID-19 from Nepal and India. In this report, we briefly describe the clinical presentation, diagnosis, and risk factors for mucormycosis and explore why patients with COVID-19 are at an increased risk for developing the infection. As treatment of mucormycosis is challenging and consumes a lot of resources, prevention of mucormycosis is pivotal in low-income countries like Nepal. We also highlight some basic steps that are easy to perform and important to reduce the risk of infection.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Gentle Sunder Shrestha, Sabin Bhandari, Ritesh Lamsal, Urmila Gurung
This work is licensed under a Creative Commons Attribution 4.0 International License.
JNMA allow to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose. The author(s) are allowed to retain publishing rights without restrictions. The JNMA work is licensed under a Creative Commons Attribution 4.0 International License. More about Copyright Policy.
